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Objectives: With a vast number of possible treatment options for Multiple 
Myeloma patients, it is unclear in which combination and sequencing compounds 
should be used to achieve prolonged overall survival. This question cannot be timely 
answered with an RCT, a health economic model (1) was used to approximate for 
OS and adopted for a German cost setting. MethOds: Using a combination of 
meta-analysis and -regression, the possible overall survival of different therapy 
sequences is approximated in a Markov model. Data source for this model is a 
systematic literature research covering 2008-2012, identifying a total of 68 studies 
and 11.115 patients in Multiple Myeloma. From each study treatment arm, response 
per therapy and therapy line was extracted. Subsequently, a regression analysis was 
used to specifically determine the “time to next treatment (TTNT)”. TTNT is used 
in our model study to reflect the positive correlation of response to therapy and 
disease progression, which has shown to be highly related (2-5). Using TTNT, the 
model can now demonstrate which sequence of therapies in 1st, 2nd and 3rd line 
will total to a possible OS of a patient. Results: We analyzed 13 sequences from 
over 200 theoretical combinations, based on their German approval. Early usage of 
new compounds results in a prolongation of overall survival of at least 6 months, 
compared to the standard therapy with melphalan/prednisone (6), with minimal 
possible OS between 3.98 and 5.06 years. Cost data from Germany were included 
to amount costs of therapy for a complete sequence. For the sequences presented, 
costs range between 69.000 and 135.000 € . The majority of those costs accrue from 
drugs, not from other resources. cOnclusiOns: An important topic of modeling 
approaches is to show both internal and external validity, which is both needed to 
validate the prognoses. The external validation is currently undertaken using data 
from cancer registries and non-interventional studies.
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Objectives: Standard therapy for chronic lymphocytic leukaemia (CLL) is fludara-
bine, followed by alemtuzumab. Patients resistant to both treatments (double refrac-
tory (DR)-CLL) receive best supportive care (BSC). Ofatumumab is licensed for the 
treatment of DR-CLL, but was not recommended by the National Institute for Health 
and Care Excellence (NICE technology appraisal 202 (TA202)). There is little clinical 
data for BSC in DR-CLL. TA202 identified a single-arm study of ofatumumab and 
an observational study of BSC. Survival for BSC in TA202 was modelled by fitting a 
Weibull distribution to data for ofatumumab non-responders. The effects of ofatu-
mumab were estimated by assuming a proportional hazards model. The objective of 
this study was to investigate the potential sources of survival data for BSC, and the 
impact of the choice of survival distributions used in TA202 on the cost-effectiveness 
of ofatumumab. MethOds: Individual patient-level data was reconstructed from 
Kaplan-Meier curves using a published algorithm. Plausible survivor functions were 
fitted to the data using Markov chain Monte-Carlo simulation. Goodness-of-fit to 
the observed data was assessed using deviance information criterion and the clini-
cal plausibility of extrapolations using subjective opinion. The cost-effectiveness 
model from TA202 was reproduced including alternative survival data. Results: 
A Weibull distribution provided the best fit to the data and was most clinically 
plausible. If proportional hazards were assumed (as in TA202) the incremental cost-
effectiveness ratio (ICER, incremental cost per life year gained) was £52,400, simi-
lar to £49,252 reported in TA202. Relaxing the assumption of proportional hazards 
increased the ICER to £85,618. cOnclusiOns: The best fitting and most clinically 
plausible model was a Weibull distribution, giving results consistent with TA202; 
however both the use of a subgroup of a single arm trial and of data from multiple 
studies has a high level of uncertainty. Relaxing the assumption of proportional 
hazards increased the ICER.
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Objectives: The VELOUR trial demonstrated significant survival benefit for afliber-
cept plus FOLFIRI (5-fluorouracil-leuocovorin-irinotecan) versus FOLFIRI alone in 
mCRC patients previously treated with oxaliplatin. Multivariate analysis identified 
a subset of “better responder” patients who derive sustained benefit with AF, which 
includes patients who did not experience an early relapse directly from adjuvant 
setting (10% of patients included in VELOUR) and with either ECOG PS0 or (PS1 and 
≤ 1 metastatic site). Median OS was significantly improved in AF arm: 16.2 versus 
13.1 months for PF (adjusted HR = 0.73 [95% CI: 0.61–0.86]). Mean survival estimation 
can render a more meaningful estimate for long-term benefit of interventions and 
can be effectively applied to clinical and economic decision support. Our objective 
was to derive mean OS for the “better responders” subgroup in VELOUR. MethOds: 
As survival probability at the end of the follow-up period was 21% in AF vs 8% in PF, 
mean OS was estimated by extrapolating the KM curve using a survival function over 
a 15-year period. Five standard parametric distributions were tested: exponential, 
Weibull, lognormal, loglogistic and Gompertz. Goodness-of-fit of distributions was 
evaluated by Akaike’s Information Criteria (AIC), Bayesian Information Criteria (BIC) 
and graphical methods. Results: Of the 1226 patients enrolled in VELOUR, 404 
Objectives: Off-label use of medications is extremely common especially in 
oncology. The aim of this study is to help update the guidelines and determine 
pharmaceuticals and off-label indications in breast cancer. MethOds: This study 
involved patients (n= 1317) with metastatic breast cancer with tumors that were 
defined as human epidermal growth factor receptor 2, ErbB-2 positive who received 
trastuzumab or other medicine application off-label usage in Turkey. During this 
period using trastuzumab was licenced only for 9 weeks, not for 52 weeks in Turkey. 
A computer search was performed using the TITCK’s ( Turkish Drug and Medical 
Devices Institution) database. The patient base was searched for off-label medi-
cine applications between 1 June 2008 to 1 June 2010. Results: The average age 
were 49.02 ± 10.46. Overall, 85 % of applications were approved in generally 8 or 9 
weeks period. It was found that the Marmara Region had the highest application 
percentage (33.26 %) and then the Central Anatolia Region (27.9 %). Evaluated on 
the base of cities Istanbul, Ankara and Izmir had the most applications with 29.6 
%, 19.2 % and 15.7 % respectively. University hospitals were created the most of 
the applications (81.1%), other applicaitons were from education & research hos-
pitals (10.2 %) and private hospitals ( 5.9 %). Off-label drug usage in breast cancer 
medication, physicians were preferred trastuzumab, trastuzumab+vinoralbin and 
lapatinib. cOnclusiOns: Trastuzumab had the highest percentage in all off-label 
medicine applications for breast cancer usage. On the other hand, 85 % of all tras-
tuzumab off-label usage applications were approved. The reason of 15 % of trastu-
zumab applications is needed to be investigated further.
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Objectives: To assess the patient population with advanced non-small cell lung 
cancer (NSCLC) with EGFR (epidermal growth factor receptor) positive mutation 
in Germany who are eligible for tyrosine-kinase inhibitor (TKI) therapy. An accu-
rate assessment of the relevant patient population provides the basis for budget 
impact analyses in health technology assessments. MethOds: A systematic litera-
ture review was conducted. In addition, data from various cancer registries, cohort 
studies and surveillance studies were analyzed and compared with the findings 
in the literature. Results: In a first step the proportion of patients with NSCLC 
was determined. Data was further differentiated by histologic subgroup (adeno-
carcinoma, large-cell carcinoma, squamous carcinoma and other carcinoma). The 
analysis revealed that the proportion of adenocarcinoma among the group of NSCLC 
has increased in Germany, especially among women from about 40% in 2000 to over 
58% in 2009, in men from 28% to almost 40%, respectively. The proportion of patients 
with locally advanced or metastatic NSCLC (stage IIIb/IV) ranged between 51%-70%. 
The proportion of patients harbouring an EGFR mutation ranged between 5%-17%, 
differing by histologic subgroup, with the highest EGFR mutation rates (9%-26%) 
in patients with adenocarcinoma. The distribution of patients by ECOG (Eastern 
Cooperative Oncology Group) Performance Status (PS) showed that at diagnosis 63%-
92% had an ECOG-PS 0-1. On average, first line therapy was received by over 80% of 
patients, while only 52%-65% underwent second line therapy and third line therapy 
was received by 15%-25% only. cOnclusiOns: By analyzing all available data it is 
possible to provide good estimates of the relevant patient population. Although 
significant advances have been made in reporting and data collection for relevant 
patient subgroups related to NSCLC, there still is a large lack of representative data 
on a national level in Germany.
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Objectives: Prostate cancer (PC) is the most common solid neoplasm in Europe. 
Accurate estimates of prevalence and patient flow through PC states are necessary 
to analyse disease burden and the health economic impact of novel therapies. This 
study presents a dynamic patient progression model (PM) estimating the popula-
tion size of 13 PC clinical states across 8 European countries (EU8; Belgium, France, 
Germany, Italy, The Netherlands, Spain, Sweden, and UK). MethOds: A dynamic 
PM was developed using a 27-year time horizon to estimate the prevalence and 
progression of PC from diagnosis through possible death, using a sequence of 13 
Markov clinical states (5 non-metastatic and 8 metastatic). Incidence data were 
taken from local country registries from 1993 to 2012, and a simple growth model 
was used to forecast incidence rates to 2020 and beyond. PM flow structure, prob-
abilities of prevalence, progression, and mortality per clinical state were determined 
using a Delphi panel of PC experts from the EU8 countries and based on published 
literature and local research. Results: A consensus of expert opinion was reached 
on the clinical states and flow rates of patients with PC in Europe. This resulted in 
a refined PM with new clinical states that represent the current treatment para-
digm for PC. The PM also estimated growth in prevalence and mortality of future 
PC patient populations across 13 different clinical states of PC from 2012 to 2020. 
Five-year prevalence rates from the PM were in agreement with those from the 
GLOBOCAN 2008 project. cOnclusiOns: The PM obtained by consensus of expert 
opinions provided patient prevalence and mortality estimates for 13 distinct PC 
clinical states. The PM and patient flow rates provide a representative simulation 
of the local environment, which can be used to assess PC disease burden, health 
economic impact, and cost of PC care in the EU.
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medium risk (OS mean time = 11.6 months, 61%) and other of low risk were obtained 
(OS mean time = 31.7 months, 38%). For NSCLC patients with immunotherapy a 
population of medium risk (OS mean time = 11.2 months, 55%); a population of 
low risk (OS mean time = 23.8 months, 33%); and another of very low risk or long-
term survival were obtained (OS mean time = 55.5 months, 12%). cOnclusiOns: 
Our analyses support the existence of several populations regarding OS among 
advanced stage lung cancer.
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Objectives: Many company submissions received by Health Technology 
Assessment (HTA) Agencies evaluate the cost effectiveness of interventions which 
impact on survival. An accurate estimate of the survival benefit is required to cal-
culate a reliable estimate of cost effectiveness. Generally the relevant trial data 
is immature and must be extrapolated. Many extrapolation models are available. 
Model choice is critical; different models can lead to different cost effectiveness 
results. The objectives were to review the methods/justification of the survival anal-
ysis used in company submissions to the National Centre for Pharmacoeconomics 
(NCPE). A further aim was to develop NCPE Guidance for the future handling of 
survival analysis. MethOds: Relevant submissions to the NCPE (economic evalu-
ations which had dealt with advanced and/or metastatic cancer) were reviewed 
to determine the methods/justification of the survival analysis used. Results: 
Twelve submissions were evaluated. Appropriately, the mean overall survival (OS) 
had been estimated and used in eight cases (67%). Median OS estimates had been 
estimated/used in three (25%). It was unclear which measure had been used in the 
remaining submission. The submissions which had used mean OS estimates were 
further investigated. Parametric model-based extrapolation techniques had been 
used to calculate the mean estimates in all eight. The most popular parametric 
models were the Weibull (n= 3) and the loglogistic (n= 3). The methods used to fit the 
parametric models varied. Most commonly the model was fitted using individual 
patient-level data. Some justification for the choice of extrapolation technique was 
offered in five submissions; AIC +/or BIC were estimated in three and visual inspec-
tion was reported in two. cOnclusiOns: Survival analysis has not been conducted 
appropriately in all HTAs. Justification of the choice of model is not always offered. 
Moving forward, NCPE Guidance is required to ensure that survival analysis using 
patient-level data is conducted appropriately. These will be presented.
CaNCer – Cost Studies
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Objectives: The 2010 Urological Association Guidelines for Management of 
Castrate-Resistant Prostate Cancer (CRPC) recommend docetaxel plus prednisone 
for first-line chemotherapy for symptomatic metastatic CRPC patients who have 
progressed from hormone therapy. Since 2010, several CRPC agents with better toler-
ability and longer survival have launched. These improved therapies are causing a 
shift in practice. The aim of our analysis was to 1) quantify the 3-year mCRPC budget 
impact for the German health system based on the practice shift, and 2) estimate 
the cost per additional month of progression-free survival (PFS). MethOds: A con-
ceptual decision analytic model was developed for the German health system to 
estimate the impact on direct medical costs of a therapy shift in CRPC over three 
years. Guideline recommended regimens were represented in model with three 
lines of therapies: palliative, abiraterone, enzalutamide, docetaxel and cabazitaxel. 
Progression in therapy was measured as the duration of PFS. A targeted literature 
search identified US per-patient-per-month costs of docetaxel treated patients (hos-
pitalization= € 954, ambulatory= € 765, ER= € 32, MD= € 318) and were adapted to the 
German health system by applying a published purchase price parity factor. Drug 
costs were based on Ex-factory pricing. Adverse event rates were used as a proxy 
to derive relative resource utilization of other treatments. Utilization of CRPC regi-
mens was informed by interviews with EU opinion leaders. Results: The shift in 
practice pattern is expected to increase the German health system’s 3-year budget 
by € 23 million. The additional cost/month of PFS is estimated to decrease by € 99/
month from € 4,659 for current treatment mix to € 4,560 for future treatment mix 
by year 3. cOnclusiOns: From the German health system’s perspective, a change 
in practice pattern will result in an increase in total budget of € 23 million. The 
reduction in cost/month of PFS of € 99/month indicates the shift in practice will 
use more efficient therapies.
PCN39
eCoNoMiC iMPaCT of deNoSuMab for SkeleTal relaTed eveNT 
PreveNTioN iN PaTieNTS wiTh ProSTaTe CaNCer aNd boNe MeTaSTaSiS 
froM a uNiTed STaTe MaNaged Care orgaNizaTioN PerSPeCTive
Arellano J.1, Cristino J.2, Chen K.3
1Amgen Inc., Thousand Oaks, CA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Amgen, Inc., 
Thousand Oaks, CA, USA
Objectives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in PrCa patients with BM to a 
MCO. MethOds: An economic model was developed to estimate clinical and eco-
nomic impact to a 1-million-member US MCO of introducing denosumab as bone 
targeting agent (BTA) for prevention of SREs in PrCa patients with BM. Total number 
of patients receiving BTA was estimated based on disease prevalence and treat-
ment eligibility in this population. The real-world SRE rates in ZA-treated patients 
were derived from a large commercial database and used together with the trial-
(66.0%) AF patients and 406 (66.1%) PF patients were classified in “better responders” 
subgroup. Lognormal and loglogistic distributions were the 2 distributions provid-
ing the best fit to the observed OS data, with very similar and good fit. Mean OS 
over 15-years using loglogistic distribution was 24.8 vs. 18.6 months for AF and PF, 
respectively. cOnclusiOns: Post-hoc analysis suggested that the “better respond-
ers” subgroup of patients within VELOUR derived enhanced survival benefit with 
the AF combination. The results highlight the therapeutic benefit of AF in clinically 
relevant patient subpopulations.
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Objectives: As cancer control strategies have become more successful, issues 
around survivorship have become increasingly important to researchers and policy 
makers. The aim of this study was to examine the role of a range of clinical and 
socio-demographic variables in explaining variations in survival after prostate 
cancer diagnosis, paying particular attention to the role of health care provider(s) 
(i.e. private vs. public) and socio-economic status. MethOds: Data were extracted 
from the National Cancer Registry Ireland, for patients diagnosed with prostate 
cancer from 1998-2009 (N= 26,183). A series of multivariate Cox and logistic regres-
sion models were used to examine the role of health care provider and socio-
economic status (area-based deprivation) on survival, controlling for age, stage, 
Gleason grade, marital status and region. Survival was based on all-cause mortal-
ity. Results: Individuals who were treated in a private care setting were more 
likely to have survived than those who had not, when other factors were controlled 
for. A socio-economic gradient was evident with respect to marital status, region 
of residence, clinical stage and Gleason grade. The effect of socio-economic status 
was modified by health care provider, such that risk of death was higher in those 
of lower socio-economic status for men treated by public, but not private, provid-
ers. cOnclusiOns: The role of health care provider (a proxy for voluntary private 
insurance) and socio-economic status in survival of men with prostate cancer may 
give rise to equity concerns regarding the operation of the Irish health care system 
and warrants further investigation.
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Objectives: There are few treatments available for advanced melanoma and sur-
vival rates are low. While the incidence of the disease continues to rise, only two 
new treatments have come to the market recently: ipilimumab and vemurafenib. 
Ipilimumab is indicated in Europe for the treatment of advanced melanoma in 
adults who have received prior therapy. Ipilimumab has demonstrated a statistically 
significant improvement in overall survival in 2 Phase III RCTs. Prolonged survival 
(> 2 years in some patients) has been shown (MDX020 & 024). MethOds: Data from 
the MDX010-20 trial, which was conducted in previously treated patients with a 
maximum follow up duration of 55 months, was used to develop an economic model 
for health technology assessment in England & Wales. This model has been used 
to predict the conditional survival (CS) of patients treated with ipilimumab (based 
on both ipilimumab containing arms) compared to gp100 – the active control. The 
model used patient level Kaplan–Meier data for the first 18 months, parametric 
curves fitted to the patient level data from 18 months to 5 years, and published AJCC 
registry data beyond 5 years. Results: The curves were a good fit to the MDX010-20 
trial data (MAE 0.003) and consistent with published Phase II data (which provides 
a longer time horizon). Given an ipilimumab patient has survived 2 years, the mod-
elled probability of being alive at 5 years is 67% (49%,79%) (gp100: 15% [9%,21%]) and 
at 10 years is 54% (39%, 63%) (gp100: 2% [1%,3%]). cOnclusiOns: The model shows 
that a substantial proportion of patients treated with ipilimumab surviving to 2 
years are likely to have sustained survival benefits: more than 50% of ipilimumab 
patients surviving to 2 years are alive at 10 years, with 29% remaining alive at 20 
years. This level of sustained survival is not shown by gp100 patients.
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Objectives: To ascertain the existence of several populations regarding overall sur-
vival (OS) in patients with advanced non-small-cell lung cancer (NSCLC). MethOds: 
Data of OS from the Cuban National Cancer Registry (CNCR) and from Cuban mul-
ticentre trials of immunotherapy were analysed with a lognormal mixed model 
assuming 1 to 6 underlying populations. The Bayesian Information Criterion (BIC) 
was used to select the best model fitted to the data in all cases. Results: The CNCR 
provided data for 31133 patients diagnosed with lung cancer since January 1998 
until December 2008. Of those, 7286 patients presented stages IIIb-IV of NSCLC at 
diagnosis and were selected for analysis. The immunotherapy Cuban trials provided 
data for more than 750 patients enrolled in 8 trials conducted since 1997 until 2010. 
The mixed model applied to CNCR data separated 4 populations: very high risk (OS 
mean time = 0.62 months, 23% of the sample); high risk (OS mean time = 3.1 months, 
34%); medium risk (OS mean time = 9.2 months, 35%); and low risk (OS mean time 
= 29.1 months, 8%). Results for clinical trials separated 2 populations for controls 
and 3 populations for the immunotherapy groups. For controls a population of 
